Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Sven Ante Lundberg M.D. | CEO, President & Executive Director | 1.11M | -- | 1963 |
| Mr. Gregory D. Perry | Chief Financial Officer | 419.1k | -- | 1960 |
| Mr. Peter B. Silverman J.D. | EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal | 781.84k | 565.02k | 1978 |
| Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor | -- | -- | -- |
| Harry Shuman | Chief Accounting Officer | -- | -- | -- |
| Mr. Cornelis Adriaan de Kruif Ph.D. | CTO & Executive VP | 349.65k | -- | 1965 |
| Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer & Senior VP | -- | -- | -- |
| Ms. Kathleen Farren | IR & Corporate Communications Officer | -- | -- | -- |
| Ms. Audrey Bergan | Chief People Officer | -- | -- | -- |
| Ms. Shannon Campbell | Executive VP & Chief Commercial Officer | -- | -- | 1966 |
Merus N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 260
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Corporate Governance
Upcoming Events
May 6, 2025 at 10:59 AM UTC - May 12, 2025 at 12:00 PM UTC
Merus N.V. Earnings Date